Vancouver, British Columbia – March 14, 2013 – Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF, Frankfurt: ZSB), announced today it has been awarded funding from Going Global Innovation. Funding from this program will go towards international travel expenses related to Sirona Biochem’s partnership meetings.
“Going Global Innovation is an excellent initiative that promotes international R&D collaborations and we are very pleased to have been awarded this funding,” commented Sirona Biochem Chief Executive Officer, Neil Belenkie. “Sirona Biochem’s scientific programs have received worldwide interest and the contribution from Going Global helps to fund the related expenses for international meetings,” he added.
About Going Global Innovation
Going Global Innovation is the innovation, science and technology pillar of the Global Commerce Support Program (GCSP) at Foreign Affairs and International Trade Canada. The objectives of Going Global are to promote and enhance Canada’s international innovation efforts by supporting Canadian companies and/or researchers in pursuing collaborative international research and development opportunities through the development of partnerships with key players in other countries and economies.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.